CD38 and Miyoshi myopathy: Indeed, anti-CD38 retreatment has become relatively common in patients exposed to multiple drug classes, as shown in a real-world study, where 36% of patients exposed to two prior therapies and 48% of patients with triple-refractory MM were retreated with daratumumab (13).